Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: the case for.
作者信息
Moyle G J, Gazzard B G, Peto T
机构信息
Kobler Clinic, Chelsea and Westminster Hospital, London.
出版信息
Genitourin Med. 1997 Jun;73(3):216-8. doi: 10.1136/sti.73.3.216.
Abstract
摘要
相似文献
1
Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: the case for.替代标志物现在为医生提供了管理抗逆转录病毒疗法的最佳手段：支持这一观点的理由。
Genitourin Med. 1997 Jun;73(3):216-8. doi: 10.1136/sti.73.3.216.
2
Better than nothing: keeping pts on failing regimen has benefits.聊胜于无：让患者继续使用失败的治疗方案是有好处的。
AIDS Alert. 2009 Apr;24(4):44-5.
3
Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?在资源有限的环境中，常规临床标志物能否用于纵向监测抗逆转录病毒治疗的成效？
Clin Infect Dis. 2007 Jan 1;44(1):135-8. doi: 10.1086/510072. Epub 2006 Nov 28.
4
[Surrogate endpoints in clinical studies exemplified by HIV infection].[以HIV感染为例的临床研究中的替代终点]
Schweiz Med Wochenschr. 1998 Jul 7;128(27-28):1079-88.
5
When to start antiretroviral therapy? NA-ACCORD stimulates the debate.何时开始抗逆转录病毒治疗？NA-ACCORD引发了这场争论。
AIDS Read. 2009 Feb;19(2):49-50, 61.
6
When to start, when to STI (or, groping for the golden moment).何时开始，何时进行性传播感染检测（或者，摸索黄金时机）
IAPAC Mon. 2001 Apr;7(4):114-7, 120-31.
7
Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia.柬埔寨感染 HIV 患者接受抗逆转录病毒治疗 4 年后的免疫病毒学结果和耐药模式。
Trop Med Int Health. 2011 Feb;16(2):205-13. doi: 10.1111/j.1365-3156.2010.02689.x. Epub 2010 Nov 19.
8
Antiretroviral rounds. First holiday was a disaster: should she take another?
AIDS Clin Care. 2004 May;16(5):40-1.
9
Effectiveness of etravirine-based therapy for treatment-experienced HIV-infected patients.基于依曲韦林的疗法对有治疗经验的HIV感染患者的疗效。
J Infect Dev Ctries. 2016 Jun 30;10(6):605-11. doi: 10.3855/jidc.7512.
10
Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.接受高效抗逆转录病毒治疗的患者体内细胞相关HIV-1 DNA早期增加。
AIDS. 1998 Dec 24;12(18):2500-2.
引用本文的文献
1
HIV, HCV and HBV: A Review of Parallels and Differences.人类免疫缺陷病毒、丙型肝炎病毒和乙型肝炎病毒：异同综述
Infect Dis Ther. 2018 Dec;7(4):407-419. doi: 10.1007/s40121-018-0210-5. Epub 2018 Sep 4.
本文引用的文献
1
Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study.血液、精液和唾液中HIV-1载量的分析：一项横断面和纵向研究中不同病毒区室的证据
AIDS. 1996 Dec;10(14):F51-6. doi: 10.1097/00002030-199612000-00001.
2
Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.血浆1型人类免疫缺陷病毒RNA水平与晚期感染患者临床进展风险的关联。艾滋病临床试验组（ACTG）116B/117研究团队。ACTG病毒学委员会耐药性和HIV-1 RNA工作组。
J Infect Dis. 1996 Oct;174(4):704-12. doi: 10.1093/infdis/174.4.704.
3
HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group.人类免疫缺陷病毒1型（HIV-1）RNA水平与临床疾病的发展。北美拉米夫定HIV工作组。
AIDS. 1996 Jul;10(8):859-65. doi: 10.1097/00002030-199607000-00009.
4
Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.齐多夫定单独使用或与去羟肌苷或扎西他滨联合使用，用于患有获得性免疫缺陷综合征或每立方毫米CD4细胞少于200个的HIV感染患者。艾滋病临床研究特里·贝恩社区项目的研究人员。
N Engl J Med. 1996 Oct 10;335(15):1099-106. doi: 10.1056/NEJM199610103351503.
5
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.每立方毫米有200至500个CD4细胞的HIV感染成年患者接受核苷治疗后病毒学和免疫学标志物与临床结局的关系。艾滋病临床试验组研究175病毒学研究团队。
N Engl J Med. 1996 Oct 10;335(15):1091-8. doi: 10.1056/NEJM199610103351502.
6
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.一项针对每立方毫米CD4细胞计数为200至500的HIV感染成人，比较核苷单药疗法与联合疗法的试验。艾滋病临床试验组研究175研究团队。
N Engl J Med. 1996 Oct 10;335(15):1081-90. doi: 10.1056/NEJM199610103351501.
7
Kinetics of viral clearance in plasma, peripheral blood mononuclear cells and lymph nodes.病毒在血浆、外周血单核细胞和淋巴结中的清除动力学。
AIDS. 1996 Jun;10(7):801-2. doi: 10.1097/00002030-199606001-00021.
8
Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons.
J Infect Dis. 1996 Aug;174(2):401-3. doi: 10.1093/infdis/174.2.401.
9
HIV viral load markers in clinical practice.临床实践中的HIV病毒载量标志物
Nat Med. 1996 Jun;2(6):625-9. doi: 10.1038/nm0696-625.
10
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.根据血浆中病毒数量预测的HIV-1感染预后。
Science. 1996 May 24;272(5265):1167-70. doi: 10.1126/science.272.5265.1167.
Zotero 插件